Clinical Trials
37 trialsGeriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
PRECISE
Case Comprehensive Cancer Center
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Astex Pharmaceuticals, Inc.
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
ICT-HCT
Fred Hutchinson Cancer Center
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
Jewish General Hospital
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Rutgers, The State University of New Jersey
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Fox Chase Cancer Center
Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk
M.D. Anderson Cancer Center
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
Radboud University Medical Center
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Pfizer
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
University of Wisconsin, Madison
Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
University of Pittsburgh
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Washington University School of Medicine
DECI2009
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Hospital Israelita Albert Einstein
DECIDER
University Hospital Freiburg
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
Groupe Francophone des Myelodysplasies
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
M.D. Anderson Cancer Center
Decitabine in Treating Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)
Eisai Inc.
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Eisai Inc.
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Astex Pharmaceuticals, Inc.
Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia
University Hospital Freiburg
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Astex Pharmaceuticals, Inc.